TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+14.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.85B
AUM Growth
+$2.85B
(+6.6%)
Cap. Flow
-$35.8M
Cap. Flow
% of AUM
-1.26%
Top 10 Holdings %
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
41
Reduced
45
Closed
16
Top Buys
| 1 |
Thermo Fisher Scientific
TMO
|
$45.7M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$36.7M |
| 3 |
Danaher
DHR
|
$33.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$22.1M |
| 5 |
DexCom
DXCM
|
$20.7M |
Top Sells
| 1 |
Amgen
AMGN
|
$44.1M |
| 2 |
Merck
MRK
|
$40.6M |
| 3 |
Pfizer
PFE
|
$36.5M |
| 4 |
AbbVie
ABBV
|
$27.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 95.34% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cigna
CI
$80.3B
| $28.3M | 0.99% | 135,712 +64,471 | +90% | +$13.4M |
|
|
27
Neurocrine Biosciences
NBIX
$13.8B
| $28.2M | 0.99% | 294,234 +231,031 | +366% | +$22.1M |
|
28
ResMed
RMD
$40.2B
| $28.1M | 0.99% | 132,344 +35,275 | +36% | +$7.5M |
|
|
29
DexCom
DXCM
$29.5B
| $27.6M | 0.97% | 74,643 +56,099 | +303% | +$20.7M |
|
30
Waters Corp
WAT
$18B
| $27.1M | 0.95% | 109,510 | – | – |
|
|
31
Pfizer
PFE
$141B
| $26M | 0.91% | 705,259 -990,509 | -58% | -$36.5M |
|
32
Moderna
MRNA
$9.37B
| $25.9M | 0.91% | 248,192 -212,167 | -46% | -$22.2M |
|
33
Exelixis
EXEL
$10.1B
| $25.2M | 0.89% | 1,256,520 +161,403 | +15% | +$3.24M |
|
34
BioMarin Pharmaceuticals
BMRN
$11.2B
| $24.4M | 0.86% | 278,330 -47,492 | -15% | -$4.16M |
|
35
Edwards Lifesciences
EW
$47.8B
| $24.2M | 0.85% | 264,955 -26,200 | -9% | -$2.39M |
|
36
Steris
STE
$24.1B
| $24M | 0.84% | 126,779 | – | – |
|
37
Alnylam Pharmaceuticals
ALNY
$58.5B
| $22.7M | 0.8% | 174,894 | – | – |
|
38
McKesson
MCK
$85.4B
| $22.7M | 0.8% | 130,448 +22,911 | +21% | +$3.98M |
|
|
PRAH
39
DELISTED
PRA Health Sciences, Inc.
PRAH
| $22.1M | 0.78% | 175,838 +96,312 | +121% | +$12.1M |
|
|
ARNA
40
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $19.4M | 0.68% | 252,971 +92,334 | +57% | +$7.09M |
|
41
Dentsply Sirona
XRAY
$2.85B
| $19.2M | 0.67% | 365,927 -42,546 | -10% | -$2.23M |
|
|
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $18.4M | 0.65% | 83,784 +5,000 | +6% | +$1.1M |
|
|
ALLK
43
DELISTED
Allakos
ALLK
| $18.3M | 0.64% | 130,937 +66,540 | +103% | +$9.32M |
|
44
argenx
ARGX
$43.6B
| $18.1M | 0.64% | 61,687 | – | – |
|
45
Acadia Pharmaceuticals
ACAD
$4.38B
| $17.7M | 0.62% | 331,789 +81,046 | +32% | +$4.33M |
|
46
Intuitive Surgical
ISRG
$170B
| $17.4M | 0.61% | 21,296 -3,773 | -15% | -$3.09M |
|
47
Idexx Laboratories
IDXX
$51.8B
| $17.4M | 0.61% | 34,814 | – | – |
|
48
AstraZeneca
AZN
$248B
| $17.2M | 0.6% | 344,333 | – | – |
|
49
Adaptive Biotechnologies
ADPT
$2.01B
| $16.9M | 0.59% | 286,013 +261,298 | +1,057% | +$15.5M |
|
50
Bio-Techne
TECH
$8.5B
| $16.4M | 0.58% | 51,710 | – | – |
|